<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0370712</journal-id>
<journal-id journal-id-type="pubmed-jr-id">3660</journal-id>
<journal-id journal-id-type="nlm-ta">Exp Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Exp. Neurol.</journal-id>
<journal-title-group>
<journal-title>Experimental neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0014-4886</issn>
<issn pub-type="epub">1090-2430</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27170209</article-id>
<article-id pub-id-type="pmc">5340082</article-id>
<article-id pub-id-type="doi">10.1016/j.expneurol.2016.05.010</article-id>
<article-id pub-id-type="manuscript">NIHMS844818</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Glial progenitor cell-based treatment of the childhood leukodystrophies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Osorio</surname>
<given-names>M. Joana</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goldman</surname>
<given-names>Steven A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY 14642</aff>
<aff id="A2"><label>2</label>Center for Basic and Translational Neuroscience, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen 2200 Denmark</aff>
<author-notes>
<corresp id="FN1">Correspondence to either: <email>osorio@sund.ku.dk</email> or <email>goldman@sund.ku.dk</email></corresp>
<corresp id="FN2"><label>*</label>Editorial correspondence to: Steve Goldman M.D., Ph.D., Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY 14642, 585-275-9550</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>16</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>08</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>07</day>
<month>3</month>
<year>2017</year>
</pub-date>
<volume>283</volume>
<issue>Pt B</issue>
<fpage>476</fpage>
<lpage>488</lpage>
<!--elocation-id from pubmed: 10.1016/j.expneurol.2016.05.010-->
<abstract>
<p id="P1">The childhood leukodystrophies comprise a group of hereditary disorders characterized by the absence, malformation or destruction of myelin. These disorders share common clinical, radiological and pathological features, despite their diverse molecular and genetic etiologies. Oligodendrocytes and astrocytes are the major affected cell populations, and are either structurally impaired or metabolically compromised through cell-intrinsic pathology, or are the victims of mis-accumulated toxic byproducts of metabolic derangement. In either case, glial cell replacement using implanted tissue or pluripotent stem cell-derived human neural or glial progenitor cells may comprise a promising strategy for both structural remyelination and metabolic rescue. A broad variety of pediatric white matter disorders, including the primary hypomyelinating disorders, the lysosomal storage disorders, and the broader group of non-lysosomal metabolic leukodystrophies, may all be appropriate candidates for glial progenitor cell-based treatment. Nonetheless, a variety of specific challenges remain before this therapeutic strategy can be applied to children. These include timely diagnosis, before irreparable neuronal injury has ensued; understanding the natural history of the targeted disease; defining the optimal cell phenotype for each disorder; achieving safe and scalable cellular compositions, designing age-appropriate controlled clinical trials; and for autologous therapy of genetic disorders, achieving the safe genetic editing of pluripotent stem cells. Yet these challenges notwithstanding, the promise of glial progenitor cell-based treatment of the childhood myelin disorders offers hope to the many victims of this otherwise largely untreatable class of disease.</p>
</abstract>
<kwd-group>
<kwd>Stem cells</kwd>
<kwd>glial progenitor cells</kwd>
<kwd>oligodendrocyte progenitor cells</kwd>
<kwd>pluripotent stem cells</kwd>
<kwd>cell therapy</kwd>
<kwd>myelin</kwd>
<kwd>remyelination</kwd>
<kwd>white matter</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>leukodystrophies</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>